Literature DB >> 17532622

Modern multimodality approach to hepatic colorectal metastases: solutions and controversies.

Vijay P Khatri1, Karen G Chee, Nicholas J Petrelli.   

Abstract

Hepatic resection for colorectal metastases, limited to the liver, has become the standard of care, and currently remains the only potentially curative therapy. Numerous single institutional reports have demonstrated long-term survival and there are no other treatment options that have shown a survival plateau. However, curative resection is possible in less than 25% of those patients with disease limited to the liver, which translates into only 5-10% of the original group developing colorectal cancer. To increase the number of patients who could benefit from hepatic resection, the last decade has seen considerable effort being directed towards novel approaches to permit curative hepatic resection such as: neoadjuvant systemic and regional chemotherapy, pre-operative portal vein embolization for hypertrophy of future liver remnant, staged hepatic resection and radio frequency ablation combined with resection for addressing multiple bilobar metastases. This article reviews development of these innovative multidisciplinary modalities and the aggressive surgical approach that has been adopted to extend the frontiers of surgical therapy for colorectal hepatic metastases.

Entities:  

Mesh:

Year:  2007        PMID: 17532622     DOI: 10.1016/j.suronc.2007.05.001

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  27 in total

Review 1.  Current treatment for colorectal liver metastases.

Authors:  Evangelos P Misiakos; Nikolaos P Karidis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

2.  Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Stacy Moulder; Siqing Fu; Sijin Wen; Aung Naing; Agop Y Bedikian; Shawn Daring; Cynthia Uehara; Chaan Ng; Michael Wallace; Luis Camacho; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-04       Impact factor: 3.333

3.  Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.

Authors:  M L Gómez Dorronsoro; R Vera; L Ortega; C Plaza; R Miquel; M García; E Díaz; M R Ortiz; J Pérez; C Hörndler; C Villar; J Antúnez; S Pereira; F López-Rios; R González-Cámpora
Journal:  Clin Transl Oncol       Date:  2013-09-10       Impact factor: 3.405

4.  Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer.

Authors:  Samer Tohme; Daniel Sukato; Gary W Nace; Albert Zajko; Nikhil Amesur; Philip Orons; Didier Chalhoub; James W Marsh; David A Geller; Allan Tsung
Journal:  HPB (Oxford)       Date:  2014-08-15       Impact factor: 3.647

Review 5.  A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases.

Authors:  Akshat Saxena; Lourens Bester; Leonard Shan; Marlon Perera; Peter Gibbs; Baerbel Meteling; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-07       Impact factor: 4.553

6.  Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases.

Authors:  Bruno C Odisio; Suguru Yamashita; Steven Y Huang; Scott E Kopetz; Kamran Ahrar; Takashi Mizuno; Claudius Conrad; Thomas A Aloia; Yun Shin Chun; Sanjay Gupta; Jean-Nicolas Vauthey
Journal:  J Vasc Interv Radiol       Date:  2018-02-01       Impact factor: 3.464

7.  Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Authors:  René Adam; Emir Hoti; Gunnar Folprecht; Al B Benson
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases.

Authors:  M Cosimelli; R Golfieri; P P Cagol; L Carpanese; R Sciuto; C L Maini; R Mancini; I Sperduti; G Pizzi; M G Diodoro; M Perrone; E Giampalma; B Angelelli; F Fiore; S Lastoria; S Bacchetti; D Gasperini; O Geatti; F Izzo
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

9.  Accomplishments in 2007 in the management of curable metastatic colorectal cancer.

Authors:  Amit Shah; Steven Alberts; René Adam
Journal:  Gastrointest Cancer Res       Date:  2008-05

10.  Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.

Authors:  D J Watkins; I Chau; D Cunningham; S S Mudan; N Karanjia; G Brown; S Ashley; A R Norman; A Gillbanks
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.